IDEXX Laboratories (IDEXX Laboratories) Debt-to-Equity : 0.72 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Debt-to-Equity?

IDEXX Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $345 Mil. IDEXX Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $723 Mil. IDEXX Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,485 Mil. IDEXX Laboratories's debt to equity for the quarter that ended in Dec. 2023 was 0.72.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for IDEXX Laboratories's Debt-to-Equity or its related term are showing as below:

IDXX' s Debt-to-Equity Range Over the Past 10 Years
Min: -105.15 Med: 1.11 Max: 7.65
Current: 0.72

During the past 13 years, the highest Debt-to-Equity Ratio of IDEXX Laboratories was 7.65. The lowest was -105.15. And the median was 1.11.

IDXX's Debt-to-Equity is ranked worse than
75.13% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs IDXX: 0.72

IDEXX Laboratories Debt-to-Equity Historical Data

The historical data trend for IDEXX Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Debt-to-Equity Chart

IDEXX Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

6.03

1.59

1.49

2.42

0.72

IDEXX Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															2.42	1.57	1.05	0.88	0.72

Competitive Comparison of IDEXX Laboratories's Debt-to-Equity

For the Diagnostics & Research subindustry, IDEXX Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDEXX Laboratories's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Debt-to-Equity falls into.

IDEXX Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

IDEXX Laboratories's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(344.799	+	722.554)	/	1484.53
	=	0.72

IDEXX Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(344.799	+	722.554)	/	1484.53
	=	0.72

IDEXX Laboratories (NAS:IDXX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

IDEXX Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEXX Laboratories (IDEXX Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (NAS:IDXX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IDXX:Mexico IX1:Germany I1DX34:Brazil IDXX:Austria

Address

One IDEXX Drive, Westbrook, ME, USA, 04092

Website

https://www.idexx.com

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.

Executives

James F Polewaczyk	officer: Corporate Vice President	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan Jay Mazelsky	director, officer: President and CEO	ONE IDEXX DRIVE, WESTBROOK ME 04092
Martin Alexander Smith	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Jonathan W Ayers	director, officer: President & CEO	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Michael Lane	officer: Executive Vice President	C/O IDEXX LABORATORIES, INC., WESTBROOK ME 04092
Irene Chang Britt	director	CAMPBELL SOUP COMPANY, ONE CAMPBELL PLACE, CAMDEN NJ 08103
Bruce L. Claflin	director	7035 RIDGE ROAD, HANOVER MD 21076
Samer Abdul Samad	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lawrence D Kingsley	director	C/O IDEX CORPORATION, 630 DUNDEE ROAD, NORTHBROOK IL 60062
Asha Collins	director	IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
M Anne Szostak	director	C/O TUPPERWARE BRANDS CORP, 14901 S ORANGE BLOSSOM TR, ORLANDO FL 32837
Sharon E. Underberg	officer: EVP, GC & Corporate Secretary	EASTMAN KODAK COMPANY, 343 STATE STREET, ROCHESTER NY 14650
Sophie V. Vandebroek	director	6 OAK MEADOW ROAD, LINCOLN MA 01770
Daniel M Junius	director	C/O IMMUNOGEN, INC., 830 WINTER STREET, WALTHAM MA 02451